Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $549.04 +3.44%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of ($12.83), $1.13 worse than the analyst estimate of ($11.70). Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.66 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.65-10.85 billion, versus the consensus of $10.762 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Power Integrations (POWI) Tops Q3 EPS by 5c; Offers Guidance
- CrossAmerica Partners (CAPL) Misses Q3 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
